Medicare Part D drugs starting with O
71 drugs start with O; 23 of them are on at least 90% of 2026 Part D formularies. Part D spending was highest for Ozempic in 2024: $13.0 billion, what plans and patients paid at the pharmacy before rebates.
Which drugs start with O?
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Octagam (immunoglobulin g, human) | 56.1% | Tier 5 | $393 million |
| Octreotide | 100% | Tier 4 | $6 million |
| Ocuflox (ofloxacin) | under 0.1% | Tier 1 | $7 thousand |
| Odactra | 5% | Tier 3 | $1 million |
| Odefsey (emtricitabine / rilpivirine / tenofovir alafenamide) | 100% | Tier 5 | $375 million |
| Odomzo (sonidegib) | 100% | Tier 5 | $46 million |
| Ofev (nintedanib) | 100% | Tier 5 | $2.1 billion |
| Ofloxacin | 100% | Tier 2 | $27 million |
| Ogsiveo (nirogacestat) | 100% | Tier 5 | $20 million |
| Ohtuvayre (ensifentrine) | 7.4% | Tier 5 | $113 thousand |
| Ojemda (tovorafenib) | 100% | Tier 5 | $705 thousand |
| Ojjaara (momelotinib) | 100% | Tier 5 | $342 million |
| Olanzapine | 100% | Tier 2 | $110 million |
| Olmesartan medoxomil | 97.5% | Tier 1 | $69 million |
| Olopatadine hydrochloride | 34.3% | Tier 4 | $4 million |
| Olpruva (sodium phenylbutyrate) | 0.1% | Tier 5 | $488 thousand |
| Olumiant (baricitinib) | 4.2% | Tier 5 | $35 million |
| Omega-3 acid ethyl esters | 92.8% | Tier 2 | $65 million |
| Omeprazole | 100% | Tier 1 | $367 million |
| Omeprazole / sodium bicarbonate | 1.2% | Tier 4 | $122 million |
| Omnaris (ciclesonide) | 0.2% | Tier 4 | $858 thousand |
| Omnitrope (somatropin) | 43.5% | Tier 5 | $10 million |
| Omvoh (mirikizumab-mrkz) | under 0.1% | Tier 2 | $5 million |
| Onapgo (apomorphine hydrochloride) | 2.5% | Tier 5 | no 2024 match |
| Ondansetron | 100% | Tier 2 | $142 million |
| Onexton (benzoyl peroxide / clindamycin phosphate) | 0.4% | Tier 4 | $63 thousand |
| Onfi (clobazam) | under 0.1% | Tier 1 | $31 million |
| Ongentys (opicapone) | 6.1% | Tier 4 | $15 million |
| Onureg (azacitidine) | 100% | Tier 5 | $86 million |
| Onyda (clonidine hydrochloride) | 0.1% | Tier 4 | no 2024 match |
| Onzetra (sumatriptan) | 0.2% | Tier 4 | no 2024 match |
| Opipza (aripiprazole) | 100% | Tier 5 | no 2024 match |
| Opsumit (macitentan) | 79.8% | Tier 5 | $1.2 billion |
| Opsynvi (macitentan / tadalafil) | 14% | Tier 5 | $24 million |
| Opvee (nalmefene) | 48.8% | Tier 3 | $7 thousand |
| Opzelura (ruxolitinib) | 3.4% | Tier 5 | $106 million |
| Oracea (doxycycline anhydrous) | under 0.1% | Tier 1 | $3 million |
| Orapred (prednisolone) | 1.9% | Tier 4 | no 2024 match |
| Orencia (abatacept) | 20.7% | Tier 5 | $248 million |
| Orenitram (treprostinil) | 37% | Tier 4 | $230 million |
Show the other 31 drugs
| Drug | Plans covering | Usual tier | Medicare spending, 2024 |
|---|---|---|---|
| Orfadin (nitisinone) | 9.5% | Tier 5 | $243 thousand |
| Orgovyx (relugolix) | 100% | Tier 5 | $484 million |
| Oriahnn (elagolix / estradiol / norethindrone) | 1.8% | Tier 5 | $289 thousand |
| Orilissa (elagolix) | 6.6% | Tier 5 | $3 million |
| Orkambi (ivacaftor / lumacaftor) | 76.1% | Tier 5 | $634 thousand |
| Orladeyo (berotralstat) | 2.2% | Tier 5 | $78 million |
| Orlynvah (probenecid / sulopenem etzadroxil) | 3.6% | Tier 5 | no 2024 match |
| Ormalvi (dichlorphenamide) | 1% | Tier 5 | no 2024 match |
| Orphenadrine citrate | 7.5% | Tier 2 | $2 million |
| Orquidea (norethindrone) | 94.1% | Tier 2 | no 2024 match |
| Orserdu (elacestrant) | 100% | Tier 5 | $259 million |
| Oseltamivir | 100% | Tier 2 | $19 million |
| Osenvelt (denosumab-bmwo) | 36.2% | Tier 5 | no 2024 match |
| Osphena (ospemifene) | 22.1% | Tier 3 | $8 million |
| Ospomyv (denosumab-dssb) | 25.1% | Tier 4 | no 2024 match |
| Otezla (apremilast) | 57.4% | Tier 5 | $1.0 billion |
| Otulfi (ustekinumab-aauz) | 18.6% | Tier 3 | no 2024 match |
| Ovide (malathion) | under 0.1% | Tier 1 | no 2024 match |
| Oxacillin | 83.3% | Tier 4 | $2 million |
| Oxaprozin | 42.9% | Tier 4 | $1 million |
| Oxazepam | 27.6% | Tier 4 | $2 million |
| Oxcarbazepine | 100% | Tier 3 | $70 million |
| Oxervate (cenegermin-bkbj) | 15.3% | Tier 5 | $715 million |
| Oxiconazole | 1.6% | Tier 4 | $7 million |
| Oxistat (oxiconazole) | 1% | Tier 4 | $246 thousand |
| Oxybutynin chloride | 100% | Tier 2 | $111 million |
| Oxycodone hydrochloride | 99.8% | Tier 3 | $134 million |
| Oxycontin (oxycodone hydrochloride) | 3.7% | Tier 1 | $338 million |
| Oxymorphone hydrochloride | 8% | Tier 4 | $20 million |
| Oxytrol (oxybutynin) | 0.2% | Tier 4 | $1 million |
| Ozempic (semaglutide) | 99% | Tier 3 | $13.0 billion |
Source: CMS Part D formulary file, 2026 second quarter; CMS Medicare Part D Spending by Drug, 2024.
What else should you check?
- Every drug, by letterAnd the 20 that cost Medicare most
- Stand-alone drug plans for 2027Premiums and deductibles
- Part D in 2027What changes for drug plans